{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:42:49Z","timestamp":1790674969810,"version":"4.1.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.clinre.2020.11.008","type":"journal-article","created":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T17:52:08Z","timestamp":1607104328000},"page":"101578","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Treatment of hepatitis C virus infection"],"prefix":"10.1016","volume":"45","author":[{"given":"Lucia","family":"Parlati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mence","family":"Hollande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislas","family":"Pol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinre.2020.11.008_bib0005","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1126\/science.2523562","article-title":"Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome","volume":"244","author":"Choo","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.clinre.2020.11.008_bib0010","author":"Assembly WHOS-NWH"},{"key":"10.1016\/j.clinre.2020.11.008_bib0015","author":"AASLD-IDSA"},{"issue":"2","key":"10.1016\/j.clinre.2020.11.008_bib0020","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jhep.2011.02.023","article-title":"EASL Clinical Practice Guidelines: mangement of chronic hepatitis C virus infection","volume":"55","author":"European Association for the Study of the Liver","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2020.11.008_bib0025","doi-asserted-by":"crossref","first-page":"981","DOI":"10.7326\/0003-4819-127-11-199712010-00006","article-title":"Reversibility of hepatic fibrosis in autoimmune hepatitis","volume":"127","author":"Dufour","year":"1997","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinre.2020.11.008_bib0030","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1053\/j.gastro.2015.08.035","article-title":"Extrahepatic morbidity and mortality of chronic hepatitis C","volume":"149","author":"Negro","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinre.2020.11.008_bib0035","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/nrgastro.2017.172","article-title":"Extra-hepatic cancers and HCV","volume":"15","author":"Pol","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"December (25)","key":"10.1016\/j.clinre.2020.11.008_bib0040","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJM198612183152503","article-title":"Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report","volume":"315","author":"Hoofnagle","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinre.2020.11.008_bib0045","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nature08463","article-title":"Genetic variation in IL28B and spontaneous clearance of hepatitis C virus","volume":"461","author":"Thomas","year":"2009","journal-title":"Nature"},{"issue":"suppl 1","key":"10.1016\/j.clinre.2020.11.008_bib0050","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1478-3231.2011.02701.x","article-title":"New targets for antiviral therapy of chronic hepatitis C","volume":"32","author":"Buhler","year":"2012","journal-title":"Liver Int"},{"key":"10.1016\/j.clinre.2020.11.008_bib0055","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","author":"Polaris Observatory, HCV Collaborators","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"September (10049)","key":"10.1016\/j.clinre.2020.11.008_bib0060","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S0140-6736(16)30579-7","article-title":"The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013","volume":"388","author":"Stanaway","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.clinre.2020.11.008_bib0065","doi-asserted-by":"crossref","DOI":"10.1136\/gutjnl-2018-316234","article-title":"Impact of sustained virological response on the extrahepatic manifestations of chronic hepatitis C: a meta-analysis","author":"Cacoub","year":"2018","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.clinre.2020.11.008_bib0070","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1056\/NEJMoa013376","article-title":"Regression of splenic lymphoma with lymphocytes after treatment of hepatitis C virus infection","volume":"347","author":"Hermine","year":"2002","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clinre.2020.11.008_bib0075","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/infdis\/jis385","article-title":"Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study","volume":"206","author":"Lee","year":"2012","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.clinre.2020.11.008_bib0080","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/hep.510240201","article-title":"An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group","volume":"24","author":"Bedossa","year":"1996","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2020.11.008_bib0085","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1476-5926-3-8","article-title":"Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C","volume":"3","author":"Poynard","year":"2004","journal-title":"Comp Hepatol"},{"issue":"5","key":"10.1016\/j.clinre.2020.11.008_bib0090","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1053\/gast.1997.v113.pm9352863","article-title":"Noninvasive diagnosis of hepatic fibrosis or cirrhosis","volume":"113","author":"Oberti","year":"1997","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.clinre.2020.11.008_bib0095","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.21669","article-title":"an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest","volume":"46","author":"Vallet-Pichard","year":"2007","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.clinre.2020.11.008_bib0100","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.jhep.2017.01.003","article-title":"A stepwise algorithm using an at-a-glance first-line test for the non-invasive diagnosis of advanced liver fibrosis and cirrhosis","volume":"66","author":"Boursier","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2020.11.008_bib0105","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1053\/j.gastro.2004.11.018","article-title":"Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C","volume":"128","author":"Cast\u00e9ra","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinre.2020.11.008_bib0110","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jhep.2014.04.044","article-title":"Non-invasive assessment of liver fibrosis with impulse elastography: comparison of Supersonic Shear Imaging with ARFI and FibroScan(R)","volume":"61","author":"Cassinotto","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2020.11.008_bib0115","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.jhep.2014.06.031","article-title":"Virology and cell biology of the hepatitis C virus life cycle: an update","volume":"61","author":"Dubuisson","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2020.11.008_bib0120","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nrmicro1645","article-title":"Replication of hepatitis C virus","volume":"5","author":"Moradpour","year":"2007","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.clinre.2020.11.008_bib0125","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1056\/NEJMe1403619","article-title":"Therapy of hepatitis C-back to the future","volume":"22","author":"Liang","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinre.2020.11.008_bib0130","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0140-6736(00)02434-X","article-title":"Recovery from chronic hepatitis C in long-term responders to ribavirin plus interferon alfa","volume":"356","author":"Fontaine","year":"2000","journal-title":"Lancet"},{"issue":"October","key":"10.1016\/j.clinre.2020.11.008_bib0135","article-title":"Evidence of HCV recovery after therapy of hepatitis C virus infection by direct acting antivirals","author":"Parlati","year":"2018","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"September (3)","key":"10.1016\/j.clinre.2020.11.008_bib0140","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/hep.27743","article-title":"Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort)","volume":"62","author":"Trinchet","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2020.11.008_bib0145","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1053\/j.gastro.2016.09.009","article-title":"Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications","volume":"152","author":"Nahon","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinre.2020.11.008_bib0150","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(18)32111-1","article-title":"for the AFEF\/ANRS Hepather CO22 cohort. Clinical outcomes in patients with chronic hepatitis C following direct-acting antiviral therapy: a prospective cohort study","volume":"393","author":"Carrat","year":"2019","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.clinre.2020.11.008_bib0155","doi-asserted-by":"crossref","first-page":"399","DOI":"10.7326\/0003-4819-149-6-200809160-00006","article-title":"Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C","volume":"149","author":"Mallet","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinre.2020.11.008_bib0160","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1136\/gutjnl-2013-306102","article-title":"Cardiovascular diseases and HCV infection: a simple association or more?","volume":"63","author":"Petta","year":"2014","journal-title":"Gut"},{"issue":"July (1)","key":"10.1016\/j.clinre.2020.11.008_bib0165","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jhep.2018.02.015","article-title":"Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis","volume":"69","author":"Petta","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2020.11.008_bib0170","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1093\/cid\/cix1007","article-title":"Declining hepatitis C virus (HCV) incidence in Dutch human immunodeficiency virus positive men who have sex with men after unrestricted access to HCV therapy","volume":"66","author":"Boerekamps","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinre.2020.11.008_bib0175","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa0808010","article-title":"Peginterferon alfa-2b or alfa-2a with ribavirin for treatement of hepatitis C infection","volume":"361","author":"Mchutchison","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinre.2020.11.008_bib0180","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.clinre.2020.11.008_bib0185","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1111\/j.1365-2036.2006.02863.x","article-title":"Review article: predicting response in hepatitis C virus therapy","volume":"23","author":"Mihm","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinre.2020.11.008_bib0190","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1086\/507307","article-title":"Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection","volume":"194","author":"Romero","year":"2006","journal-title":"J Infect Dis"},{"issue":"November (6963)","key":"10.1016\/j.clinre.2020.11.008_bib0195","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/nature02099","article-title":"An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus","volume":"426","author":"Lamarre","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.clinre.2020.11.008_bib0200","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jhep.2013.04.035","article-title":"CUPIC Study Group. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) \u2014 NCT01514890","volume":"59","author":"H\u00e9zode","year":"2013","journal-title":"J Hepatol"},{"issue":"January (1)","key":"10.1016\/j.clinre.2020.11.008_bib0205","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jhep.2016.08.021","article-title":"ANRS\/AFEF HEPATHER study group. Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients","volume":"66","author":"Pol","year":"2017","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.clinre.2020.11.008_bib0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/M15-0785","article-title":"Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic HCV genotype 1, 4, or 6 infection: a randomized trial","volume":"163","author":"Zeuzem","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinre.2020.11.008_bib0215","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/COH.0b013e3281ca6fd2","article-title":"Hepatotoxicity and liver disease in the context of HIV therapy","volume":"2","author":"Vogel","year":"2007","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.clinre.2020.11.008_bib0220","article-title":"Clinical management of drug-drug interactions in HCV therapy: challenges and solutions","author":"Burger","year":"2012","journal-title":"J Hepatol"},{"issue":"November (19)","key":"10.1016\/j.clinre.2020.11.008_bib0225","first-page":"1886","article-title":"Bradyarrhythmias associated with sofosbuvir treatment","volume":"373","author":"Fontaine","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinre.2020.11.008_bib0230","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa1702417","article-title":"Glecaprevir\u2013pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection","volume":"378","author":"Zeuzem","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinre.2020.11.008_bib0235","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jhep.2017.03.039","article-title":"High SVR rates upon 8- or 12-week treatment with glecaprevir and pibrentasvir in patients with chronic HCV genotype 1\u20136 infection without cirrhosis","volume":"67","author":"Kwo","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2020.11.008_bib0240","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMoa1704053","article-title":"Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment","volume":"377","author":"Gane","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinre.2020.11.008_bib0245","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jhep.2018.03.007","article-title":"High SVR12 with 8-week and 12-week glecaprevir\/pibrentasvir therapy: an integrated analysis of HCV genotype 1\u20136 patients without cirrhosis","volume":"69","author":"Puoti","year":"2018","journal-title":"J Hepatol"},{"issue":"January (2)","key":"10.1016\/j.clinre.2020.11.008_bib0250","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/apt.14423","article-title":"Sofosbuvir and velpatasvir with or without voxilaprevir in direct-acting antiviral-na\u00efve chronic hepatitis C: patient-reported outcomes from POLARIS 2 and 3","volume":"47","author":"Younossi","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinre.2020.11.008_bib0255","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1053\/j.gastro.2017.03.047","article-title":"Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 phase 3 randomized trials","volume":"153","author":"Jacobson","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinre.2020.11.008_bib0260","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1056\/NEJMoa1613512","article-title":"Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection","volume":"376","author":"Bourli\u00e8re","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinre.2020.11.008_bib0265","first-page":"1128","article-title":"HCV transmission in industrialized countries and resource-constrained areas","author":"Thursz","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.clinre.2020.11.008_bib0270","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.jhep.2017.06.033","article-title":"Micro-elimination \u2014 a path to global elimination of hepatitis C","volume":"67","author":"Lazarus","year":"2017","journal-title":"J Hepatol"},{"issue":"November","key":"10.1016\/j.clinre.2020.11.008_bib0275","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jviromet.2018.08.019","article-title":"Performance of a new rapid diagnostic test for the detection of antibodies to hepatitis C virus","volume":"261","author":"Poiteau","year":"2018","journal-title":"J Virol Methods"},{"issue":"March (3)","key":"10.1016\/j.clinre.2020.11.008_bib0280","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/liv.14315","article-title":"In-field evaluation of Xpert\u00ae HCV viral load Fingerstick assay in people who inject drugs in Tanzania","volume":"40","author":"Mohamed","year":"2020","journal-title":"Liver Int"},{"issue":"11","key":"10.1016\/j.clinre.2020.11.008_bib0285","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1136\/gutjnl-2017-315783","article-title":"Development and clinical validation of the Genedrive point-of-care test for qualitative detection of hepatitis C virus","volume":"67","author":"Llibre","year":"2018","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.clinre.2020.11.008_bib0290","doi-asserted-by":"crossref","first-page":"68394","DOI":"10.1093\/cid\/civ948","article-title":"Risk of late relapse or reinfection with hepatitis C virus after achieving a sustained virological response: a systematic review and meta-analysis","volume":"62","author":"Simmons","year":"2016","journal-title":"Clin Infect Dis"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740120303442?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740120303442?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:29:26Z","timestamp":1761895766000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740120303442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":58,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S2210740120303442"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2020.11.008","relation":{},"ISSN":["2210-7401"],"issn-type":[{"value":"2210-7401","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of hepatitis C virus infection","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2020.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101578"}}